PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Experimental Medicine & Immunotherapeutics, School of Clinical Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Electronic address: mf503@medschl.cam.ac.uk.\', \'Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.\', \'King\'s College London, Strand, London, WC2R 2LS, UK.\', \'Division of Experimental Medicine & Immunotherapeutics, School of Clinical Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK; Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.\', \'Department of Rheumatology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.\', \'Clinical Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1094-5539(21)00047-X10.1016/j.pupt.2021.102035
?:doi
?:hasPublicationType
?:journal
  • Pulmonary pharmacology & therapeutics
is ?:pmid of
?:pmid
?:pmid
  • 33933611
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33933611>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33933611>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all